New Assessment System in Measuring Symptom Distress in Cancer Patients

StatusRecruiting
PhaseNot specified
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. 6 versions Re-verified since May 6, 2024, no change to tracked fieldsv45-v50
  2. Primary completion date: Apr 30, 2030 to Apr 30, 2031v44
  3. Site contact updatedv43
  4. Primary completion date: Apr 30, 2020 to Apr 30, 2030
    • Study completion date: Apr 30, 2020 to Apr 30, 2031
    v42
  5. 2 versions Re-verified since Feb 11, 2020, no change to tracked fieldsv40-v41
Show 38 earlier versionsHide 38 earlier versions
  1. Primary endpoints: 5 to 8
    • Enrollment target: 5500 to 6500
    v39
  2. Primary endpoints: 1 to 5v38 Show 11 more changesShow less
    • Enrollment target: 5000 to 5500
    • Primary completion date: Apr 2020 to Apr 30, 2020
    • Study completion date: Apr 2021 to Apr 30, 2020
    • Start date: Apr 1999 to Apr 13, 1999
    • Interventions: Survey (Behavioral) to Interview (Other), Quality-of-Life Assessment (Other), Questionnaire Administration (Other)
    • Study description shortened, about 160 words
    • Study site revised
    • Collaborators: 6 to 7
    • Study title revised
    • Eligibility criteria shortened, about 1 word
    • Secondary endpoints shortened, about 4 words
  3. Collaborators: 4 to 6v37
  4. Study completion date: Apr 2020 to Apr 2021
    • Eligibility criteria expanded, about 4 words
    v36
  5. Enrollment target: 4500 to 5000
    • Study description shortened, about 35 words
    v35
  6. Primary and study completion dates: Apr 2019 to Apr 2020v34
  7. Collaborators: 3 to 4v33
  8. Primary completion date: Apr 2018 to Apr 2019
    • Study completion date: Apr 2019
    v32
  9. 3 versions Re-verified since Jun 23, 2016, no change to tracked fieldsv29-v31
  10. Primary completion date: Apr 2017 to Apr 2018v28
  11. Enrollment target: 3500 to 4500
    • Study description revised
    v27
  12. Study description expanded, about 1 wordv26
  13. Primary completion date: Apr 2016 to Apr 2017
    • Study description shortened, about 22 words
    • Eligibility criteria expanded, about 1 word
    v25
  14. Enrollment target: 2500 to 3500
    • Eligibility criteria expanded, about 110 words
    • Study description shortened, about 3 words
    v24
  15. Collaborators: 2 to 3v23
  16. Enrollment target: 2450 to 2500
    • Eligibility criteria shortened, about 6 words
    • Collaborators expanded, about 4 words
    v22
  17. Study description expanded, about 13 words
    • Study site revised
    v21
  18. Primary completion date: Apr 2015 to Apr 2016v20
  19. 2 versions Re-verified since Nov 14, 2013, no change to tracked fieldsv18-v19
  20. Primary completion date: Apr 2014 to Apr 2015
    • Study description expanded, about 161 words
    v17
  21. Re-verified, no change to tracked fieldsv16
  22. Enrollment target: 1950 to 2450
    • Study description revised
    v15
  23. Re-verified, no change to tracked fieldsv14
  24. Primary completion date: Apr 2012 to Apr 2014v13
  25. Eligibility criteria expanded, about 4 words
    • Study description expanded, about 2 words
    v12
  26. Study description revisedv11
  27. Re-verified, no change to tracked fieldsv10
  28. Primary completion date: Apr 2011 to Apr 2012v9
  29. Study site revisedv8
  30. Primary completion date: Apr 2009 to Apr 2011v7
  31. Primary endpoint revised
    • Secondary endpoints: 2 to 1
    v6
  32. Study title expanded, about 4 wordsv5
  33. Study description revisedv4
  34. Primary endpoint revisedv3
  35. Primary completion date: Apr 2009
    • Interventions: M.D. Anderson Inventory (MDASI) (Behavioral) to Survey (Behavioral)
    • Eligibility criteria revised
    • Study arms: 0 to 1
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial studies how well a new assessment system (MDASI or other MD Anderson-developed PRO instrument) works in measuring symptoms and the impact on quality of life in cancer patients. Development of a new assessment system may provide more information about the common symptoms that may occur in patients due to cancer and its treatment and how the symptoms impact quality of life.
Trial Details
NCT Number NCT00505245
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: National Cancer Institute (NCI), Bayer, Bristol-Myers Squibb, Eli Lilly and Company, Genentech, Inc., Merck Sharp & Dohme LLC, National Institutes of Health (NIH)
Conditions
(from sponsor)		 Caregiver, Health Care Provider, Malignant Neoplasm, Physician
Related terms Neoplasms
Enrollment 6,500 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov